Evidence map›Paper›PMID 38169944›Full record

ArticleThe Lancet regional health. Western Pacific2024

The genomic epidemiology of

Lex E X Leong, Rosa C Coldbeck-Shackley, Mark McMillan, Holly B Bratcher, Mark Turra, Andrew Lawrence, Charlene Kahler, Martin C J Maiden, Geraint B Rogers, Helen Marshall

Registry-linked trialAbstract read
In one paragraph

Article in The Lancet regional health. Western Pacific, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03089086 (South Australian Meningococcal B Vaccine Herd Immunity Study), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03089086 phase4completednot on this map

South Australian Meningococcal B Vaccine Herd Immunity Study

TypeinterventionalSponsorUniversity of AdelaideRan2017 to 2018Enrolled34,489ConditionsMeningococcal DiseaseArmsLicensed 4CMenB vaccine
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lex E X LeongMicrobiology and Infectious Diseases, SA Pathology, Adelaide 5000, Australia.
Rosa C Coldbeck-ShackleyMicrobiology and Infectious Diseases, SA Pathology, Adelaide 5000, Australia.
Mark McMillanVaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide 5000, Australia.
Holly B BratcherDepartment of Biology, University of Oxford, 11a Mansfield Road, Oxford, United Kingdom.
Mark TurraMicrobiology and Infectious Diseases, SA Pathology, Adelaide 5000, Australia.
Andrew LawrenceMicrobiology and Infectious Diseases, SA Pathology, Adelaide 5000, Australia.
Charlene KahlerThe University of Western Australia, Perth 6009, Australia.
Martin C J MaidenDepartment of Biology, University of Oxford, 11a Mansfield Road, Oxford, United Kingdom.
Geraint B RogersMicrobiome & Host Health, South Australian Health and Medical Research Institute, Bedford Park, 5042, Australia.
Helen MarshallVaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide 5000, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Oropharyngeal carriage of Methods: A total 34,489 oropharyngeal samples were collected as part of a state-wide cluster randomised-controlled trial in South Australia during 2017 and 2018 (NCT03089086). Samples were screened for the presence of Findings: Unencapsulated meningococci were predominant at baseline (36.3% of isolates), followed by MenB (31.0%), and MenY (20.5%). Most MenB were ST-6058 from hyperinvasive cc41/44, or ST-32 and ST-2870 from cc32. For MenY, ST-23 and ST-1655 from cc23 were prevalent. Meningococcal carriage was mostly unchanged due to the vaccination programme; however, a significant reduction in ST-53 capsule-null meningococci prevalence was observed in 2018 compared to 2017 (OR = 0.52; 95% CI: 0.30-0.87, p = 0.0106). This effect was larger in the vaccinated compared to the control group (OR = 0.37; 95% CI: 0.12-0.98, p = 0.0368). Interpretation: While deployment of the 4CMenB vaccination did not alter the carriage of hyperinvasive MenB in the vaccinated population, it altered the carriage of other Funding: This work was funded by GlaxoSmithKline Biologicals SA.

Indexed as

Asymptomatic meningococcal carriageNeisseria meningitidisVaccinationWhole genome sequencing

Identifiers

PMID38169944
PMCPMC10758868

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.